Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04274153 · ClinicalTrials.gov registry record · Phase 4
HPV Vaccination Study in Postpartum Women
A Phase 4 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 225
- Enrollment target
NCT04274153: Completed Phase 4 study, sponsored by Johns Hopkins University.
NCT04274153 is a Phase 4 study that has completed, run by Johns Hopkins University. The registered enrollment target is 225 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04274153, a Phase 4 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 225 participants
- Enrollment target
Study Summary
The human papillomavirus (HPV) is the most common sexually transmitted infection (STI) in the United States (U.S.) and is responsible for a wide range of conditions, including cancers within the anogenital tract and the oropharynx. In just the U.S. alone, it's estimated that HPV causes 330,000 cases of precancerous cervical dysplasia and 12,000 cases of cervical cancer. The investigators propose a 2-dose HPV vaccination study in women seeking postpartum care at Johns Hopkins University. The investigators will measure the immunogenicity and acceptability of the vaccine in the postpartum setting.
Primary Outcome
Measure the immunogenicity of a two-dose 9-valent HPV vaccination regimen in postpartum women previously unvaccinated against the HPV 16 virus. Immunogenicity will be assessed by the antibody responses. The Geometric mean titers will be measured using milli Merck units (mMU)/mL.
Interventions
- BIOLOGICAL Gardasil9
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2020-08-03 |
| Est. Completion | 2023-02-01 |
| Phase | Phase 4 |
What the finished NCT04274153 record still lists
NCT04274153 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 1 intervention - of which Gardasil9 is the first listed.
NCT04274153 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04274153 about?
NCT04274153 is a clinical study titled "HPV Vaccination Study in Postpartum Women". The human papillomavirus (HPV) is the most common sexually transmitted infection (STI) in the United States (U.S.) and is responsible for a wide range of conditions, including cancers within the anogenital tract and the oropharynx. In just the U.S. alone, it's estimated that HPV causes 330,000 cases...
What is the current status of trial NCT04274153?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 225 participants. The study started on 2020-08-03. Estimated completion is 2023-02-01.
What interventions are being tested in trial NCT04274153?
The interventions under investigation include: Gardasil9 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04274153?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04274153's enrollment target sits among peer trials
225 379th of 2000 higher than 1,622 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI